H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on PDS Biotechnology (PDSB – Research Report) today and set a price target of $15.00. The company’s shares closed last Friday at $7.42.
According to TipRanks.com, Pantginis has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -8.7% and a 27.7% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Actinium Pharmaceuticals.
PDS Biotechnology has an analyst consensus of Moderate Buy, with a price target consensus of $18.50.
The company has a one-year high of $17.85 and a one-year low of $2.02. Currently, PDS Biotechnology has an average volume of 388K.
Based on the recent corporate insider activity of 8 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of PDSB in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. The company was founded on March 15, 2019 and is headquartered in Berkeley Heights, NJ.
Read More on PDSB:
- H.C. Wainwright Remains a Buy on Cytokinetics (CYTK)
- Jackson Financial Incorporation (JXN) Gets a Hold Rating from Morgan Stanley
- Morgan Stanley Maintains Their Hold Rating on Pulmonx (LUNG)
- Morgan Stanley Sticks to Their Hold Rating for Envista Holdings (NVST)
- Morgan Stanley Sticks to Its Hold Rating for TransMedics Group (TMDX)